Virtus Investment Advisers Inc. Sells 79,371 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Virtus Investment Advisers Inc. trimmed its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 50.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,897 shares of the biotechnology company's stock after selling 79,371 shares during the quarter. ADMA Biologics makes up approximately 1.2% of Virtus Investment Advisers Inc.'s portfolio, making the stock its 13th largest position. Virtus Investment Advisers Inc.'s holdings in ADMA Biologics were worth $1,557,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. State Street Corp grew its stake in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock valued at $259,970,000 after acquiring an additional 4,945,063 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after purchasing an additional 92,281 shares during the period. Driehaus Capital Management LLC grew its position in ADMA Biologics by 17.3% during the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company's stock valued at $33,860,000 after purchasing an additional 447,743 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in ADMA Biologics by 28.7% during the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company's stock valued at $28,868,000 after purchasing an additional 575,100 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on ADMA shares. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. Finally, HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

Insider Buying and Selling at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. The trade was a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Stock Up 2.6 %

Shares of NASDAQ:ADMA traded up $0.50 on Friday, reaching $19.82. The company had a trading volume of 2,164,386 shares, compared to its average volume of 3,287,482. The stock has a 50-day moving average price of $19.10 and a 200 day moving average price of $15.68. The stock has a market capitalization of $4.69 billion, a P/E ratio of 70.79 and a beta of 0.70. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the business posted $0.01 EPS. On average, equities analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.